Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus

被引:3
|
作者
Shrivastav, Dharmsheel [1 ]
Singh, Desh Deepak [1 ]
机构
[1] Amity Univ Rajasthan, Amity Inst Biotechnol, SP 1 Kant Kalwar,NH 11C, Jaipur 303002, Rajasthan, India
关键词
Type 2 diabetes mellitus; MicroRNAs; Advanced glycation end products; Receptor for advanced glycation end products; GLYCATION END-PRODUCTS; INFLAMMATION; MIRNAS; CELLS; ACTIVATION; PROFILES; RECEPTOR; PATHWAY; DISEASE; RISK;
D O I
10.12998/wjcc.v12.i3.525
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Type 2 diabetes mellitus (T2DM) is a metabolic disease of impaired glucose utilization. Uncontrolled high sugar levels lead to advanced glycation end products (AGEs), which affects several metabolic pathways by its receptor of advanced glycation end products (RAGE) and causes diabetic complication. MiRNAs are small RNA molecules which regulate genes linked to diabetes and affect AGEs pathogenesis, and target tissues, influencing health and disease processes. AIM To explore miRNA roles in T2DM's metabolic pathways for potential therapeutic and diagnostic advancements in diabetes complications. METHODS We systematically searched the electronic database PubMed using keywords. We included free, full-length research articles that evaluate the role of miRNAs in T2DM and its complications, focusing on genetic and molecular disease mechanisms. After assessing the full-length papers of the shortlisted articles, we included 12 research articles. RESULTS Several types of miRNAs are linked in metabolic pathways which are affected by AGE/RAGE axis in T2DM and its complications. miR-96-5p, miR-7-5p, miR-132, has_circ_0071106, miR-143, miR-21, miR-145-5p, and more are associated with various aspects of T2DM, including disease risk, diagnostic markers, complications, and gene regulation. CONCLUSION Targeting the AGE/RAGE axis, with a focus on miRNA regulation, holds promise for managing T2DM and its complications. MiRNAs have therapeutic potential as they can influence the metabolic pathways affected by AGEs and RAGE, potentially reducing inflammation, oxidative stress, and vascular complications. Additionally, miRNAs may serve as early diagnostic biomarkers for T2DM. Further research in this area may lead to innovative therapeutic strategies for diabetes and its associated complications.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus
    Shroff, Geeta
    WORLD JOURNAL OF STEM CELLS, 2016, 8 (07): : 223 - 230
  • [32] Therapeutic approaches to Type 2 diabetes mellitus
    Rose, ML
    Paulik, MA
    Lenhard, JM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (09) : 1223 - 1236
  • [33] Targeting gut microbiota in type 2 diabetes mellitus: Potential roles of dietary flavonoids
    Han, Shuai
    Luo, Yi
    Hu, Zuomin
    Qin, Dandan
    Luo, Feijun
    FOOD BIOSCIENCE, 2022, 45
  • [34] Profiling peripheral microRNAs in obesity and type 2 diabetes mellitus
    Wu, Liangping
    Dai, Xiaojiang
    Zhan, Junfang
    Zhang, Yuxin
    Zhang, Hongbin
    Zhang, Hongbing
    Zeng, Songhua
    Xi, Wenbin
    APMIS, 2015, 123 (07) : 580 - 585
  • [35] Role and therapeutic potential of microRNAs in diabetes
    Kolfschoten, I. G. M.
    Roggli, E.
    Nesca, V.
    Regazzi, R.
    DIABETES OBESITY & METABOLISM, 2009, 11 : 118 - 129
  • [36] Bioactive lipids, MICRORNAs, GPCRs and type 2 diabetes mellitus
    Das, Undurti N.
    AGRO FOOD INDUSTRY HI-TECH, 2011, 22 (02): : 22 - 23
  • [37] Fine-tuning of microRNAs in Type 2 Diabetes Mellitus
    Rosado, Juan A.
    Diez-Bello, Raquel
    Salido, Gilles M.
    Jardin, Isaac
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (22) : 4102 - 4118
  • [38] Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus
    Park, Sangmi S.
    Ortega, Romy Rodriguez
    Agudelo, Christina W.
    Perez, Jessica Perez
    Gandara, Brais Perez
    Garcia-Arcos, Itsaso
    McCarthy, Cormac
    Geraghty, Patrick
    MEDICINA-LITHUANIA, 2021, 57 (04):
  • [39] SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
    Ghosh, Raktim Kumar
    Ghosh, Samhati Mondal
    Chawla, Shalini
    Jasdanwala, Sarfaraz Abdeli
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04): : 457 - 463
  • [40] Emerging roles of exosomal miRNAs in diabetes mellitus
    He, Xiaoyun
    Kuang, Gaoyan
    Wu, Yongrong
    Ou, Chunlin
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (06):